Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: A single center experience

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 9, 2013, Pages 1533-1539

  Singh, Tripti ^a   Maw, Thin Thin ^a   Henry, Brian L ^b   Pastor Soler, Núria M ^a   Unruh, Mark L ^d   Hallows, Kenneth R ^a   Nolin, Thomas D ^a,c  

^a Renal Electrolyte Division   (United States)

^b SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CREATININE; DABIGATRAN; HEMOGLOBIN;

AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; COLON VOLVULUS; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS HEMODIAFILTRATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA;

ACCIDENTAL FALLS; ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; BLOOD TRANSFUSION; COLONIC DISEASES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTESTINAL PERFORATION; INTESTINAL VOLVULUS; LEG ULCER; MALE; RENAL DIALYSIS; SUBARACHNOID HEMORRHAGE;

EID: 84883668874     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01570213     Document Type: Article

References (34)

1. US Food and Drug Administration: FDA Drug Safety Communication: Safety Review of Post-Market Reports of Serious Bleeding Events with the Anticoagulant Pradaxa (Dabigatran Etexilate Mesylate), 2011. Available at: www.fda.gov/Drugs/DrugSafety/ucm282724.htm#sa. Accessed January 21, 2013
2. Boehringer Ingelheim Pharmaceuticals, Inc.: Pradaxa (Dabigatran Etexilate Mesylate) Prescribing Information, 2012. Available at: www.pradaxa.com. Accessed January 21, 2013
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151, 2009
4. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S: Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123: 2363-2372, 2011
5. Stangier J, Stahle H, Rathgen K, Fuhr R: Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47: 47-59, 2008
6. Stangier J: Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47: 285-295, 2008
7. Stangier J, Clemens A: Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15[Suppl 1]: 9S-16S, 2009
8. US Food and Drug Administration: FDA Drug Safety Communication: Update on the Risk for Serious Bleeding Events with the Anticoagulant Pradaxa (Dabigatran Etexilate Mesylate), 2012. Available at: www.fda.gov/Drugs/DrugSafety/ucm326580.htm. Accessed January 21, 2013
9. Cotton BA, McCarthy JJ, Holcomb JB: Acutely injured patients on dabigatran. N Engl J Med 365: 2039-2040, 2011
10. Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW: Dabigatran: Review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 7: 281-287, 2011
11. Battinelli EM: Reversal of new oral anticoagulants. Circulation 124: 1508-1510, 2011
12. Moore TJ, Furberg CD, Cohen MR: Anticoagulants: The Leading Reported Drug Risk in 2011: May 31, 2012: New Data from 2011 Quarters 3-4. QuarterWatch 2012, 2012. Available at: www.ismp.org/quarterwatch/pdfs/2011Q4.pdf. Accessed January 21, 2013
13. Chen BC, Viny AD, Garlich FM, Basciano P, Howland MA, Smith SW, Hoffman RS, Nelson LS: Hemorrhagic complications associated with dabigatran use. Clin Toxicol (Phila) 50: 854-857, 2012
14. Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, Drouet L, Payen D: The use of dabigatran in elderly patients. Arch Intern Med 171: 1285-1286, 2011
15. Harper P, Young L, Merriman E: Bleeding risk with dabigatran in the frail elderly. N Engl J Med 366: 864-866, 2012
16. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW: Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119: 2172-2174, 2012
17. Cano EL, Miyares MA: Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother 10: 160-163, 2012
18. Wychowski MK, Kouides PA: Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 46: e10, 2012
19. Harinstein LM, Morgan JW, Russo N: Treatment of dabigatranassociated bleeding: Case report and review of the literature [published online ahead of print November 16, 2012]. J Pharm Pract
20. Kamboj J, Kottalgi M, Cirra VR, Shah N, Kamboj R: Direct thrombin inhibitors: A case indicating benefit from 'plasmapheresis' in toxicity: A call for establishing "guidelines" in overdose and to find an "antidote!" Am J Ther 19: e182-e185, 2012
21. Chang DN, Dager WE, Chin AI: Removal of dabigatran by hemodialysis. Am J Kidney Dis 61: 487-489, 2013
22. Stangier J, Rathgen K, Stahle H, Mazur D: Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, singlecentre study. Clin Pharmacokinet 49: 259-268, 2010
23. Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, Neumayer HH, Liesenfeld KH, Lehr T, Hartter S, Friedman J, Peters H, Clemens A: Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 109: 596-605, 2013
24. Hart RG, Eikelboom JW, Ingram AJ, Herzog CA: Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 8: 569-578, 2012
25. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A: Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103: 1116-1127, 2010
26. Hankey GJ, Eikelboom JW: Dabigatran etexilate: A new oral thrombin inhibitor. Circulation 123: 1436-1450, 2011
27. Lavergne V, Nolin TD, Hoffman RS, Roberts D, Gosselin S, Goldfarb DS, Kielstein JT, Mactier R, Maclaren R, Mowry JB, Bunchman TE, Juurlink D, Megarbane B, Anseeuw K, Winchester JF, Dargan PI, Liu KD, Hoegberg LC, Li Y, Calello DP, Burdmann EA, Yates C, Laliberté M, Decker BS, Mello-Da-Silva CA, Lavonas E, Ghannoum M: The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: Guideline methodology. Clin Toxicol (Phila) 50: 403-413, 2012
28. Takki S, Gambertoglio JG, Honda DH, Tozer TN: Pharmacokinetic evaluation of hemodialysis in acute drug overdose. J Pharmacokinet Biopharm 6: 427-442, 1978
29. Singh SM, McCormick BB, Mustata S, Thompson M, Prasad GV: Extracorporeal management of valproic acid overdose: A large regional experience. J Nephrol 17: 43-49, 2004
30. HYPHEN Biomed: Hemoclot Thrombin Inhibitors Product Information, 2011. Available at: http://www.aniara.com/pdf/INS-ACK002L-RUO.pdf. Accessed March 19, 2013
31. Liesenfeld KH, Schafer HG, Trocóniz IF, Tillmann C, Eriksson BI, Stangier J: Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: A population model analysis. Br J Clin Pharmacol 62: 527-537, 2006
32. Halbmayer WM, Weigel G, Quehenberger P, Tomasits J, Haushofer AC, Aspoeck G, Loacker L, Schnapka-Koepf M, Goebel G, Griesmacher A: Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med 50: 1601-1605, 2012
33. Nowak G: The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 33: 173-183, 2003
34. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W: The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64: 292-303, 2007